Related Experiment Video
Updated: Dec 28, 2025
Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening
Published on: January 10, 2025
Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery
Ling F Ye1, Eduard Reznik1, Joshua M Korn2
1Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
Abstract:
There is a compelling need for new therapeutic strategies for glioblastoma multiforme (GBM). Preclinical target and therapeutic discovery for GBMs is primarily conducted using cell lines grown in serum-containing media, such as U-87 MG, which do not reflect the gene expression profiles of tumors found in GBM patients. To address this lack of representative models, we sought to develop a panel of patient-derived GBM models and characterize their genomic features, using RNA sequencing (RNA-seq) and growth characteristics, both when grown as neurospheres in culture, and grown orthotopically as xenografts in mice. When we compared these with commonly used GBM cell lines in the Cancer Cell Line Encyclopedia (CCLE), we found these patient-derived models to have greater diversity in gene expression and to better correspond to GBMs directly sequenced from patient tumor samples. We also evaluated the potential of these models for targeted therapy, by using the genomic characterization to identify small molecules that inhibit the growth of distinct subsets of GBMs, paving the way for precision medicines for GBM.
Insights
Developing patient-derived glioblastoma models offers a more accurate preclinical platform. These models better reflect patient tumors, enabling the discovery of targeted therapies for glioblastoma multiforme (GBM).
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Glioblastoma multiforme (GBM) requires novel therapeutic strategies.
- Current preclinical models, like U-87 MG cell lines, do not accurately represent patient tumor gene expression.
- This limitation hinders effective drug discovery for GBM.
Purpose of the Study:
- To develop and characterize a panel of patient-derived GBM models.
- To compare these models with established cell lines for genomic and growth fidelity.
- To identify potential targeted therapies based on patient-derived model characteristics.
Main Methods:
- Generation of patient-derived GBM models (neurospheres and orthotopic xenografts).
- Genomic characterization using RNA sequencing (RNA-seq).
- Comparison with cell lines from the Cancer Cell Line Encyclopedia (CCLE).
Main Results:
- Patient-derived models exhibited greater gene expression diversity compared to CCLE cell lines.
- These models demonstrated higher concordance with primary GBM tumors.
- Genomic data identified small molecules targeting distinct GBM subsets.
Conclusions:
- Patient-derived GBM models provide a more representative preclinical platform.
- These models facilitate the identification of precision medicines for glioblastoma.
- This approach advances targeted therapy development for GBM patients.
